Skip to main content
. Author manuscript; available in PMC: 2011 Mar 15.
Published in final edited form as: Clin Cancer Res. 2010 Mar 9;16(6):1781–1789. doi: 10.1158/1078-0432.CCR-09-1913

Figure 3.

Figure 3

Effects of Smo siRNA and recombinant ShhN treatment on Gli1 mRNA expression in pancreatic CAFs. (a) Smo and (b) Gli1 levels were assessed by qRT-PCR in CAF26 cells transfected with 2μM non-targeting or Smo siRNA for 72 hours. (c) CAF27 cells were transfected with 2μM non-targeting or Smo siRNA and treated with the indicated concentrations of recombinant ShhN 48 hours later. Gli1 mRNA levels were assessed at 72 hours post-transfection. Relative Smo or Gli1 mRNA levels after normalization to the corresponding 18S rRNA levels are shown. Data represent the mean of three independent experiments; error bars are SD values.

HHS Vulnerability Disclosure